Higher Adenoma Detection Rates at Screening Associated With Lower Long-Term Colorectal Cancer Incidence and Mortality.
Adenoma Detection Rate
Colorectal Cancer
Flexible Sigmoidoscopy
Screening
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
02
09
2020
accepted:
09
09
2020
pubmed:
16
9
2020
medline:
17
3
2022
entrez:
15
9
2020
Statut:
ppublish
Résumé
Detection and removal of adenomas reduces colorectal cancer (CRC) risk. The impact of adenoma detection rates (ADRs) on long-term CRC incidence and mortality is unknown. We investigated this using data from the UK Flexible Sigmoidoscopy Screening Trial. Of 167,882 UK Flexible Sigmoidoscopy Screening Trial participants, 40,085 were in the intervention arm and underwent flexible sigmoidoscopy screening at 13 trial centers. The median follow-up time was 17 years. At each center, 1 endoscopist performed most flexible sigmoidoscopies. Multivariable logistic regression was used to classify centers into high-, intermediate-, and low-detector groups based on their main endoscopist's ADR. We calculated the incidence and mortality of distal and all-site CRC, and estimated hazard ratios (HRs) with 95% CIs using Cox regression. Five, 4, and 4 centers, respectively, were classified into the high-detector, intermediate-detector, and low-detector groups. The average ADRs in each respective group were 15%, 12%, and 9%. Distal CRC incidence and mortality were reduced among those screened compared with controls in all groups, and effects of screening varied significantly by detector ranking, with larger reductions in incidence and mortality seen in the high-detector group (incidence: HR, 0.34; 95% CI, 0.27-0.42; mortality: HR, 0.22, 95% CI, 0.13-0.37) than in the low-detector group (incidence: HR, 0.55; 95% CI, 0.44-0.68; mortality: HR, 0.54; 95% CI, 0.34-0.86). Similar results were observed for all-site CRC, with larger effects seen in the high-detector (incidence: HR, 0.58; 95% CI, 0.50-0.67; mortality: HR, 0.52; 95% CI, 0.39-0.69) than in the low-detector group (incidence: HR, 0.72; 95% CI, 0.61-0.85; mortality: HR, 0.68; 95% CI, 0.51-0.92), although the heterogeneity was not statistically significant. Higher ADRs at screening provide greater long-term protection against CRC incidence and mortality. Isrctn.org, number: ISRCTN28352761.
Sections du résumé
BACKGROUND & AIMS
Detection and removal of adenomas reduces colorectal cancer (CRC) risk. The impact of adenoma detection rates (ADRs) on long-term CRC incidence and mortality is unknown. We investigated this using data from the UK Flexible Sigmoidoscopy Screening Trial.
METHODS
Of 167,882 UK Flexible Sigmoidoscopy Screening Trial participants, 40,085 were in the intervention arm and underwent flexible sigmoidoscopy screening at 13 trial centers. The median follow-up time was 17 years. At each center, 1 endoscopist performed most flexible sigmoidoscopies. Multivariable logistic regression was used to classify centers into high-, intermediate-, and low-detector groups based on their main endoscopist's ADR. We calculated the incidence and mortality of distal and all-site CRC, and estimated hazard ratios (HRs) with 95% CIs using Cox regression.
RESULTS
Five, 4, and 4 centers, respectively, were classified into the high-detector, intermediate-detector, and low-detector groups. The average ADRs in each respective group were 15%, 12%, and 9%. Distal CRC incidence and mortality were reduced among those screened compared with controls in all groups, and effects of screening varied significantly by detector ranking, with larger reductions in incidence and mortality seen in the high-detector group (incidence: HR, 0.34; 95% CI, 0.27-0.42; mortality: HR, 0.22, 95% CI, 0.13-0.37) than in the low-detector group (incidence: HR, 0.55; 95% CI, 0.44-0.68; mortality: HR, 0.54; 95% CI, 0.34-0.86). Similar results were observed for all-site CRC, with larger effects seen in the high-detector (incidence: HR, 0.58; 95% CI, 0.50-0.67; mortality: HR, 0.52; 95% CI, 0.39-0.69) than in the low-detector group (incidence: HR, 0.72; 95% CI, 0.61-0.85; mortality: HR, 0.68; 95% CI, 0.51-0.92), although the heterogeneity was not statistically significant.
CONCLUSIONS
Higher ADRs at screening provide greater long-term protection against CRC incidence and mortality. Isrctn.org, number: ISRCTN28352761.
Identifiants
pubmed: 32931959
pii: S1542-3565(20)31280-5
doi: 10.1016/j.cgh.2020.09.020
pmc: PMC8811539
pii:
doi:
Banques de données
ISRCTN
['ISRCTN28352761']
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e148-e167Subventions
Organisme : Department of Health
ID : 16/65/01
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C53889/A25004
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Gastroenterology. 2008 May;134(5):1570-95
pubmed: 18384785
Stat Med. 1997 May 15;16(9):1017-29
pubmed: 9160496
Gut. 2016 Dec;65(12):1923-1929
pubmed: 27531829
Lancet. 2017 Apr 1;389(10076):1299-1311
pubmed: 28236467
Gastroenterology. 2017 Jul;153(1):98-105
pubmed: 28428142
Gastrointest Endosc. 2020 Jan;91(1):135-141
pubmed: 31499041
N Engl J Med. 1992 Mar 5;326(10):658-62
pubmed: 1736104
Gastrointest Endosc. 2020 Aug;92(2):355-364.e5
pubmed: 32092289
Am J Gastroenterol. 2018 Dec;113(12):1855-1861
pubmed: 30072776
Gastroenterology. 2018 Oct;155(4):1059-1068.e2
pubmed: 29935150
N Engl J Med. 2014 Apr 3;370(14):1298-306
pubmed: 24693890
Gastroenterology. 2015 Aug;149(2):356-66.e1
pubmed: 25911510
N Engl J Med. 2010 May 13;362(19):1795-803
pubmed: 20463339
Gastroenterology. 2004 May;126(5):1247-56
pubmed: 15131784
Lancet. 2010 May 8;375(9726):1624-33
pubmed: 20430429
BMJ. 2017 Jan 13;356:i6673
pubmed: 28087510
Lancet Gastroenterol Hepatol. 2019 Mar;4(3):239-247
pubmed: 30655218
Lancet. 2002 Apr 13;359(9314):1291-300
pubmed: 11965274
Clin Gastroenterol Hepatol. 2013 Jan;11(1):73-8
pubmed: 22902761
Gastrointest Endosc. 2018 Aug;88(2):209-222.e11
pubmed: 29614263